Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 211

Results For "FY"

2296 News Found

Junk food and low physical activity leading to diabetes: ASSOCHAM report
News | November 15, 2021

Junk food and low physical activity leading to diabetes: ASSOCHAM report

Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India


Zydus Cadila receives tentative approval for IBS tablets
Drug Approval | November 15, 2021

Zydus Cadila receives tentative approval for IBS tablets

The group now has 324 approvals and has so far filed over 400 ANDAs


Sudeep Pharma ventures into nutrition
Healthcare | November 11, 2021

Sudeep Pharma ventures into nutrition

Sudeep Nutrition will be a one-stop solution for food, beverage, nutraceuticals and nutritional product manufacturers


India Pharmaceutical Market grows 5% in October 2021
News | November 10, 2021

India Pharmaceutical Market grows 5% in October 2021

Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22


Zydus Cadila receives approval for glycopyrrolate injection
Drug Approval | November 10, 2021

Zydus Cadila receives approval for glycopyrrolate injection

Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated


Sanofi to invest up to US $ 60 million in Gyroscope
Startup | November 09, 2021

Sanofi to invest up to US $ 60 million in Gyroscope

A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).


UK authorises first Covid-19 pill
News | November 05, 2021

UK authorises first Covid-19 pill

Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency


Venus Remedies H1 net profit rises 315%
News | November 03, 2021

Venus Remedies H1 net profit rises 315%

Venus Remedies has reported consolidated financial results for the period ended September 30, 2021


Thermo Fisher Scientific realigns product portfolio
Medical Device | November 02, 2021

Thermo Fisher Scientific realigns product portfolio

Consolidation of the Acros Organics, Alfa Aesar and Maybridge brands to one single brand, Thermo Scientific


Built-for-purpose offering for biomolecule attribute monitoring
Medical Device | November 02, 2021

Built-for-purpose offering for biomolecule attribute monitoring

The Thermo Scientific Orbitrap Exploris MX enables customer success by combining high-quality data with operational simplicity